Genome&Company Inc

Genome&Company Inc has a market price of 6860.0 KRW and a market cap of 237,690,678,820 KRW, with a price-to-book ratio of 2.25 and a price-to-tangible-book ratio of 2.25. The company's liquidity position is characterized by a current ratio of 2.29 and cash and equivalents of 15,598,068,700 KRW, but it has a negative net cash position after subtracting total debt. The debt-to-equity ratio is 0.18, indicating a relatively low leverage position. The company's profitability is weak, with a return on equity of -6.08% and a return on assets of -4.43%. These metrics are below the industry norms for biotechnology firms, which typically require high R&D investment and long development cycles. The operating income is -36,904,579,720 KRW, and the net income is -6,428,092,300 KRW, reflecting ongoing losses. Genome&Company Inc operates through three segments: New Drug Development, CDMO, and Consumer. The New Drug Development segment focuses on anticancer drugs and microbiome medicines, while the CDMO segment provides microbiome therapeutic contract development and manufacturing services. The Consumer segment is engaged in microbiome cosmetics and health functional food. Revenue concentration data is not provided, but the company's exposure to the healthcare diagnostics activity suggests a focus on niche therapeutic areas. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The operating cash flow is -18,386,763,810 KRW, and the free cash flow is -1,556,884,450 KRW, indicating ongoing cash outflows. The capital expenditure of -497,659,560 KRW suggests some investment in infrastructure, but the overall financial position remains challenging. The risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt underscores the company's liquidity constraints. The dilution potential is low, and no significant adjustments have been applied to the valuation metrics. Recent events and filings have not been detailed in the provided data, but the company's ongoing losses and negative cash flows suggest a need for continued monitoring of its financial health and strategic initiatives.